The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Single Nucleotide Polymorphisms of Human STING Can Affect Innate Immune Response to Cyclic Dinucleotides
Open accessAbstract
The STING (stimulator of interferon genes) protein can bind cyclic dinucleotides to activate the production of type I interferons and inflammatory cytokines. The cyclic dinucleotides can be bacterial second messengers c-di-GMP and c-di-AMP, 3'5'-3'5' cyclic GMP-AMP (3'3' cGAMP) produced by Vibrio cholerae and metazoan second messenger 2'5'-3'5' Cyclic GMP-AMP (2'3' cGAMP). Analysis of single nucleotide polymorphism (SNP) data from the 1000 Genome Project revealed that R71H-G230A-R293Q (HAQ) occurs in 20.4%, R232H in 13.7%, G230A-R293Q (AQ) in 5.2%, and R293Q in 1.5% of human population. In the absence of exogenous ligands, the R232H, R293Q and AQ SNPs had only modest effect on the stimulation of IFN-β and NF-κB promoter activities in HEK293T cells, while HAQ had significantly lower intrinsic activity. The decrease was primarily due to the R71H substitution. The SNPs also affected the response to the cyclic dinucleotides. In the presence of c-di-GMP, the R232H variant partially decreased the ability to activate IFN-βsignaling, while it was defective for the response to c-di-AMP and 3'3' cGAMP. The R293Q dramatically decreased the stimulatory response to all bacterial ligands. Surprisingly, the AQ and HAQ variants maintained partial abilities to activate the IFN-β signaling in the presence of ligands due primarily to the G230A substitution. Biochemical analysis revealed that the recombinant G230A protein could affect the conformation of the C-terminal domain of STING and the binding to c-di-GMP. Comparison of G230A structure with that of WT revealed that the conformation of the lid region that clamps onto the c-di-GMP was significantly altered. These results suggest that hSTING variation can affect innate immune signaling and that the common HAQ haplotype expresses a STING protein with reduced intrinsic signaling activity but retained the ability to response to bacterial cyclic dinucleotides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., & Kumar, S. (2011) · Molecular Biology and Evolution · doi:10.1093/molbev/msr121 · Cited by 39,969
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“STING, also known as MITA, MPYS, ERIS, and TMEM173, was recognized as the signaling adaptor in the innate immune response [6-8], that could detect cytosolic dsDNA through distinct DNA sensors [2-5,9,10].”
BackgroundCyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1229963 · Cited by 2,541
Niesen, F. H., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,408
Crosstalk in NF-κB Signaling Pathways
Oeckinghaus, A., Hayden, M. S., & Ghosh, S. (2011) · Nature Immunology · doi:10.1038/ni.2065 · Cited by 1,942
AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
Fernandes-Alnemri, T., Yu, J.-W., Datta, P., Wu, J., & Alnemri, E. S. (2009) · Nature · doi:10.1038/nature07710 · Cited by 1,831 · cited 1×
“STING, also known as MITA, MPYS, ERIS, and TMEM173, was recognized as the signaling adaptor in the innate immune response [6-8], that could detect cytosolic dsDNA through distinct DNA sensors [2-5,9,10].”
Background
Cited by
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
Decout, A., Katz, J. D., Venkatraman, S., & Ablasser, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00524-z · Cited by 2,309
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
An orally available non-nucleotide STING agonist with antitumor activity
Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., et al. (2020) · Science · doi:10.1126/science.aba6098 · Cited by 694
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
“Sequence analysis indicated that 2 of the 11 CA cells (LoVo and SW480) exhibited a previously reported HAQ STING variant (Jin et al., 2011; Yi et al., 2013), which occurs in approximately 20% of the population, and which has been reported to be partially defective when overexpressed in 293T cells,…”
BackgroundThe host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458
DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway
Lau, L., Gray, E. E., Brunette, R. L., & Stetson, D. B. (2015) · Science · doi:10.1126/science.aab3291 · Cited by 453
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.047 · Cited by 451
Rodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 383
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes
Almine, J. F., O’Hare, C. A. J., Dunphy, G., Haga, I. R., Naik, R. J., Atrih, A., Connolly, D. J., Taylor, J., Kelsall, I. R., Bowie, A. G., et al. (2017) · Nature Communications · doi:10.1038/ncomms14392 · Cited by 340
Oduro, P. K., Zheng, X., Wei, J., Yang, Y., Wang, Y., Zhang, H., Liu, E., Gao, X., Du, M., & Wang, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.011 · Cited by 339
Prolonged activation of innate immune pathways by a polyvalent STING agonist
Li, S., Luo, M., Wang, Z., Feng, Q., Wilhelm, J., Wang, X., Li, W., Wang, J., Cholka, A., Fu, Y.-X., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00675-9 · Cited by 317
Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes
Cerboni, S., Jeremiah, N., Gentili, M., Gehrmann, U., Conrad, C., Stolzenberg, M.-C., Picard, C., Neven, B., Fischer, A., Amigorena, S., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161674 · Cited by 299
IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP
Jønsson, K. L., Laustsen, A., Krapp, C., Skipper, K. A., Thavachelvam, K., Hotter, D., Egedal, J. H., Kjolby, M., Mohammadi, P., Prabakaran, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms14391 · Cited by 283
The STING pathway and the T cell-inflamed tumor microenvironment
Woo, S.-R., Corrales, L., & Gajewski, T. F. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.003 · Cited by 271
Dampened STING-Dependent Interferon Activation in Bats
Xie, J., Li, Y., Shen, X., Goh, G., Zhu, Y., Cui, J., Wang, L.-F., Shi, Z.-L., & Zhou, P. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.01.006 · Cited by 269
Baird, J. R., Friedman, D., Cottam, B., Dubensky, T. W., Kanne, D. B., Bambina, S., Bahjat, K., Crittenden, M. R., & Gough, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3619 · Cited by 257
Role of the cGAS–STING pathway in cancer development and oncotherapeutic approaches
Khoo, L. T., & Chen, L. (2018) · The EMBO Reports · doi:10.15252/embr.201846935 · Cited by 204
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Metadata
- Authors
- Yi, G., Brendel, V. P., Shu, C., Li, P., Palanathan, S., & Cheng Kao, C.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-21
- Volume
- 8
- Issue
- 10
- Pages
- e77846
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2027163190
- Cited by
- 270
- References
- 45
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.